Healthcare private equity (PE) investment firm Ampersand Capital Partners has made a multi-million dollar investment in contract topical and transdermal product manufacturer MedPharm.
While the exact figure has not been disclosed, a spokesperson from MedPharm told us the investment will be used to further grow its business.
“Up to now MedPharm has been self-funded and grown organically,” we were told. “Whilst we have had double digit annual growth for the last three years and expanded successfully in the US, we now need access to additional capital to strategically exploit the major opportunities we see in our chosen markets.”
MedPharm’s services include formulation development, performance testing, clinical supply manufacture and drug administration technologies, including transdermal and ocular delivery platforms.
Ampersand, meanwhile, is invested in a number of pharma and healthcare service firms, including fellow contract manufacturing organisations (CMOs) Brammer Bio, LakePharma, and Avista Pharma.
But while MedPharm said it is aware that Ampersand invests in several complimentary areas, we were told: “There are no immediate plans to leverage these as we concentrate on MedPharm’s existing strategic plan.”